To ask the Secretary of State for Health, what estimate he has made of the number of lung cancer patients who would benefit from the immunotherapy nivolumab; and if he will make a statement.
Answered on
14 October 2015
NHS England has advised that it is not currently possible to estimate the numbers of patients in England who will be suitable for treatment, as the licence for nivolumab has been split into two distinct sub-groups (squamous and non-squamous non-small cell lung cancer) and the latter has yet to receive a marketing authorisation.
Answered by
Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.